ASCO 2017 | The impact of TRK inhibitor LOXO-101 (larotrectinib) on patients with TRK fusion cancers

Howard Burris

Howard A. Burris, MD, FASCO from the Sarah Cannon Research Institute, Nashville, TN discusses the TRK inhibitor LOXO-101 (larotrectinib) and its impact on patients with TRK fusion cancers (NCT02576431, NCT02122913, NCT02637687). Dr Burris emphasizes that this highlights the importance of looking at the molecular profile of patients.
This interview was recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL.

Share this video  
2nd June 2017

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter